Corpseed

CDSCO Circular on NSAIDs and Antibiotics 2026: What Pharmacies, Doctors and Hospitals Need to Know

Department: Department of Health and Family WelfareAuthority: Central Drugs Standard Control OrganisationPublish: Applicable: 21-09-2026Product Quality ComplianceMedical Device and Pharmaceutical

Quick note

Below is the official summary and the reference document preview. Use “Open PDF” for full screen view.

Schedule a Call Back

IN +91

2,100+ CDSCO medical device assignments since 2018

Clients include Endolite India, Mankind Pharma, Ossur India, ADK Health Care, Credence Prosthetic India, V2U Physio Asia, International Electro Medical Company, Radimage Healthcare India, Istok New Hearing AID, Simpladent Implant Solutions, Starkey Laboratories India, Gentec Medical (12 of 1,100+ served since 2018).

A few more clients we've served in this industry
Pharma and healthcare
Endolite India · Mankind Pharma · Ossur India · ADK Health Care · Credence Prosthetic India · V2U Physio Asia · International Electro Medical Company · Radimage Healthcare India · Istok New Hearing AID · Simpladent Implant Solutions · Starkey Laboratories India · Gentec Medical · Cureesse Pharma · Hygiene Medicus · Nexus Surgical and Medicare
More clients
Meditronix Corporation · Nilkamal · Haesi GHL · GHL · Servotech Power Systems · Elektrocraft India · Happy Medicare · Anantaa Gsk Innovations · Cogmac Technologies · Aficionados Tech · Superceuticals · Truevis Technologies · 1008 Digital Health · BDS Services · Evoq Imaging Technologies · Premier Medical Systems and Devices · Riransa · Vitrag Infra Projects · Insta Biotech · Digital Acoustics · Artificial Learning Systems India · Nfilade Security Solutions · Humors Tech · K2O Consulting
See our CDSCO medical device service →

Summary

The Central Drugs Standard Control Organization (CDSCO) has issued a circular dated 21 September 2026 on the indiscriminate use of painkillers, particularly non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics and the associated risk of Chronic Kidney Disease. The circular is addressed not only to doctors. It also speaks directly to pharmacists, retailers, distributors, hospitals, healthcare institutions, patients and State/UT Drugs Control Authorities. 

The main message is straightforward: these medicines should not be used casually, repeatedly or for longer than medically required. CDSCO also reminds stakeholders that prescription and sale conditions already apply under the Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945.

For pharmacies and hospitals, this is not a new registration exercise. The real task is to look at existing dispensing, prescribing and monitoring practices and check whether they are being followed properly.

CDSCO Circular at a Glance

Particular Details
Issuing authority Central Drugs Standard Control Organization, Government of India
Administrative setup Directorate General of Health Services
Division New Drugs Division
Document type Circular
File number F. No. Legal-11018(11)/177/2026-eoffice
Date 21 September 2026
Subject Indiscriminate use of painkillers (NSAIDs), antibiotics and associated risk of Chronic Kidney Disease
Main law referred to Drugs and Cosmetics Act, 1940
Rules referred to Drugs Rules, 1945
Schedules mentioned G, H, H1 and X
Main medicines discussed NSAIDs/painkillers and antibiotics
Key stakeholders Public, healthcare professionals, pharmacists, retailers, distributors, hospitals and drug-control authorities
Main focus Responsible prescribing, prescription-based sale, safe use and antimicrobial stewardship
New CDSCO registration created No
New licence created No
Separate compliance deadline Not expressly specified
New government fee Not expressly specified
New standalone penalty Not expressly specified

The circular is therefore better read as a regulatory reminder and responsible-use direction, not as a fresh licensing scheme.

Why Has CDSCO Issued This Circular?

The circular comes from a practical concern: medicines that need medical supervision can cause problems when they are repeatedly taken without advice or supplied without proper checks.

CDSCO's concern with NSAIDs is closely linked to kidney-related risk. It specifically asks people with pre-existing kidney disease or other factors that may affect renal function to tell their healthcare professional before using NSAIDs. Healthcare professionals are also asked to consider renal impairment, dehydration, cardiovascular disease and other relevant conditions before prescribing these medicines.

Antibiotics raise a different concern. Unnecessary treatment, incorrect choice, wrong dosing or extended treatment can contribute to poor medicine use and antimicrobial resistance. The circular therefore asks both prescribers and patients to use antibiotics more carefully.

At the end of the document, CDSCO ties these directions to three broad outcomes it wants stakeholders to avoid:

  • preventable adverse drug reactions,
  • renal complications, and
  • antimicrobial resistance.

This is why the document does more than ask patients to be careful. It puts responsibility on every stage of the medicine-use chain.

Does the Circular Create a New Rule?

Not in the sense of creating an entirely new drug-control framework.

The circular refers back to the Drugs and Cosmetics Act, 1940 and Drugs Rules, 1945. Prescription requirements, conditions of retail sale and prescribed warnings already arise from that framework. The 2026 circular brings those obligations back into focus and adds detailed stakeholder-wise advice on responsible use.

That difference matters.

The pharmacy should not consider the prescription requirement to start on 21 September 2026. Similarly, the hospital should not consider antimicrobial stewardship as the licence condition introduced under this document. The better way to understand the circular is:

Area Existing Regulatory Position What CDSCO Is Stressing in 2026
Prescription medicines Applicable prescription conditions already exist Follow them strictly
Schedule H/H1 sale Controlled by existing Drugs Rules Do not bypass prescription requirements
Labelling warnings Existing warning requirements apply Observe them in practice
NSAID prescribing Medical supervision is required where applicable Consider patient risk, dose and duration
Antibiotic use Prescription and responsible use framework exists Avoid unnecessary and inappropriate treatment
Hospital controls Existing clinical systems continue Strengthen monitoring and stewardship
Public behaviour Patients should follow medical advice Avoid self-medication and reuse of leftover antibiotics

So, businesses do not need to search for a new portal or registration form merely because this circular has been issued.

The Regulatory Framework Behind the Circular

India's drug-regulation framework controls the import, manufacture, sale and distribution of medicines through the Drugs and Cosmetics Act, 1940 and the Rules made under it.

The CDSCO circular refers to Schedules G, H, H1 and X of the Drugs Rules, 1945. These schedules are relevant because particular medicines may be subject to different levels of medical supervision, warnings and conditions of sale.

The circular does not attempt to give a full legal exposition of each schedule. Its immediate function is more limited, namely, to remind concerned parties that prescription-controlled medicines should be treated according to the respective regulations.

Two schedules receive particular attention:

  • Schedule H, because CDSCO states that most NSAIDs fall under it, and
  • Schedule H1, because the circular states that most antibiotic drugs fall under this schedule.

That wording should be kept intact. “Most” does not mean “all”.

Which Drug Schedules Are Mentioned?

Schedule G

Schedule G is referred to as part of the wider group of medicines that may require medical supervision.

The circular does not go into a detailed medicine-by-medicine Schedule G list, so businesses should not use the circular alone to classify a product.

Schedule H

Schedule H is particularly relevant to the NSAID discussion.

CDSCO states that most NSAIDs are included in Schedule H. For medicines falling under applicable Schedule H prescription controls, retail sale is linked to a prescription from a Registered Medical Practitioner.

Schedule H1

The circular states that most antibiotic drugs are included in Schedule H1.

This schedule is discussed because of both prescription controls and prescribed warning requirements.

Schedule X

Schedule X is also mentioned as part of the regulatory framework, though the circular does not build its main directions around Schedule X products.

For businesses, the practical point is simple: classification should be checked product by product. A broad label such as “painkiller” or “antibiotic” is not enough for a legal compliance decision.

How Are NSAIDs Treated Under the Circular?

NSAIDs are a central part of this circular because of the kidney-related concerns identified by CDSCO.

The circular says that most NSAIDs fall under Schedule H. It therefore reinforces the importance of applicable prescription-based retail sale conditions.

But the document goes further than retail sale.

Healthcare professionals are asked to consider:

  • why the medicine is being prescribed,
  • the patient's age,
  • existing illnesses,
  • medicines already being taken,
  • kidney-related risk factors, and
  • other conditions that may raise the risk associated with NSAID use.

This makes the circular relevant to both pharmacies and hospitals.

For a pharmacy, the issue is whether sale conditions are being followed.

For a prescriber, the issue is whether the medicine is clinically justified and being used carefully.

Lowest Effective Dose and Shortest Appropriate Duration

CDSCO specifically asks healthcare professionals to consider the lowest effective dose for the shortest appropriate duration when prescribing NSAIDs, particularly where the patient has an increased risk of renal impairment.

It must not be converted to a rigid dosage regimen. The circular does not provide for:

  • one standard dose,
  • one standard number of tablets,
  • one standard duration of treatment, or
  • one standard method for all patients.

These are all clinical issues.

The regulatory message is simply that unnecessary exposure should be avoided, especially where kidney-related risk is already present.

What Patients with Kidney-Related Risk Factors Should Know

CDSCO gives direct advice to individuals with pre-existing kidney disease or other factors that may increase the risk of renal impairment.

Such individuals should inform their healthcare professional before using NSAIDs.

This section of the circular should be read carefully. CDSCO is not saying that every NSAID will cause kidney disease. Nor does it say that medically supervised NSAID treatment is automatically unsafe.

The concern is the combination of:

  • indiscriminate use,
  • repeated use,
  • prolonged use,
  • existing risk factors, and
  • absence of proper medical supervision.

That is the correct context for the kidney-risk warning.

How Are Antibiotics Treated Under Schedule H1?

The circular states that most antibiotic drugs are included in Schedule H1.

That brings two things into focus.

First, applicable prescription conditions must be followed.

Second, antibiotic use needs greater clinical discipline.

CDSCO asks healthcare professionals to prescribe antibiotics judiciously and in line with antimicrobial stewardship principles.

This means the prescribing decision should consider, where relevant:

  • the likely cause of infection,
  • the site of infection,
  • severity,
  • microbiological investigation,
  • local susceptibility patterns,
  • selection of the medicine,
  • dose, and
  • duration of treatment.

The circular is therefore not anti-antibiotic. It is against unnecessary and inappropriate antibiotic use.

What Does CDSCO Say About Schedule H1 Labelling?

The circular also refers to warning language required for Schedule H1 medicines.

The warning broadly conveys that the medicine should be used in accordance with medical advice and should not be sold at retail without the prescription of a Registered Medical Practitioner.

CDSCO links prescribed warnings, cautions and conditions of sale to Rule 97 of the Drugs Rules, 1945.

For pharmacies, this is more than a packaging issue.

Staff dealing with such products should know:

why the warning is there,

what sale conditions apply,

when a prescription is required, and

why casual supply can become a compliance problem.

A label requirement works only when the people selling the medicine understand it.

Can Pharmacies Sell NSAIDs and Antibiotics Without Prescription?

The answer depends on the regulatory classification of the particular medicine.

It would be inaccurate to say that every medicine described as a painkiller or antibiotic has one identical legal status.

What the circular does say is that statutory requirements relating to Schedule H, H1 and other prescription drugs must be strictly followed. It also tells pharmacists and retailers not to encourage or facilitate self-medication involving antibiotics or prescription-only NSAIDs.

For a medical store, the practical compliance question should therefore be:

Which schedule does this product fall under, and what conditions apply to its retail sale?

That is a better approach than relying on broad product categories.

Who Is Covered by the CDSCO Circular?

Stakeholder Main Direction Immediate Area of Attention
General public Avoid indiscriminate use Self-medication
Patients using NSAIDs Seek medical advice for repeated/prolonged use Kidney-related risk
Patients using antibiotics Follow prescribed treatment Do not share or reuse leftovers
Doctors/prescribers Prescribe only where clinically indicated Clinical justification
Pharmacists Follow prescription-sale conditions Dispensing
Retail drug sellers Do not facilitate self-medication Sale practices
Distributors Follow statutory sale/distribution requirements Regulatory handling
Hospitals Strengthen rational prescribing Monitoring and review
Healthcare institutions Improve stewardship and counselling Internal systems
State/UT Drugs Control Authorities Create awareness and support compliance Regulatory outreach

This broad stakeholder coverage is one reason the circular should not be treated as a pharmacy-only update.

CDSCO Advice for the General Public

The directions for the public are practical and direct.

Avoid Repeated or Prolonged Self-Use

NSAIDs/painkillers and antibiotics should not be taken repeatedly or for prolonged periods without medical advice.

The idea is not to create fear around ordinary treatment. It is to stop unsupervised medicine use from becoming routine.

Do Not Use Antibiotics for Self-Medication

CDSCO advises that antibiotics should not be used on one's own where treatment has not been clinically indicated.

The circular specifically refers to conditions such as most uncomplicated viral infections.

Follow the Prescribed Treatment

Where a healthcare professional has prescribed an antibiotic, patients are advised to take it as directed.

That means the patient should not independently change the course of treatment.

Do Not Share Antibiotics

A medicine prescribed to one person should not be passed to someone else simply because the symptoms appear similar.

Do Not Reuse Leftover Antibiotics

Leftover antibiotics should not become a substitute for a fresh clinical assessment.

The circular expressly discourages this practice.

Seek Advice When Symptoms Continue

In cases where the pain, fever, or any other symptom recurs, it is recommended that people seek professional guidance from doctors rather than continue to take medicines themselves.

CDSCO Directions for Doctors and Healthcare Professionals

The circular places considerable responsibility on prescribers.

Prescribe Only When There Is a Clinical Need

NSAIDs and antibiotics should be prescribed only where they are clinically indicated.

This is the first filter.

The fact that a patient has pain, fever or signs of infection does not by itself remove the need for clinical assessment.

Look at the Whole Patient, Not Just the Symptom

CDSCO asks healthcare professionals to consider:

  • clinical condition,
  • age,
  • comorbidities,
  • concurrent medicines, and
  • relevant risk factors.

This becomes especially important for NSAIDs where kidney-related risk is involved.

Take Additional Precautions Where Risk Is Higher

The circular identifies patients with:

  • renal impairment,
  • dehydration,
  • cardiovascular disease, and
  • other conditions that may increase the risk associated with NSAIDs.

These situations call for closer clinical consideration before and during treatment.

Avoid Unnecessary Antibiotic Combinations

CDSCO specifically warns against unnecessary combination therapy.

This means antibiotics should not be combined merely as a routine approach where there is no clinical need.

Avoid Incorrect Antibiotic Selection

Choosing an antibiotic should be based on the patient's clinical picture and, where relevant, microbiological information and local susceptibility patterns.

Avoid Incorrect Dose and Unnecessary Duration

The circular also identifies incorrect dosing and unnecessarily prolonged antibiotic treatment as practices that should be avoided.

What Is Antimicrobial Stewardship?

Antimicrobial stewardship is simply a structured approach to using antibiotics responsibly.

The aim is not to avoid antibiotics altogether. It is to make sure they are used when needed and in an appropriate way.

Under the CDSCO circular, responsible antibiotic prescribing includes attention to:

  • whether the treatment is clinically warranted,
  • the likely causative agent,
  • site of infection,
  • severity of the infection,
  • microbiological information,
  • susceptibility pattern in that locality,
  • choice of drug,
  • dosage, and
  • duration of treatment.

Hospitals and healthcare institutions are specifically asked to strengthen antimicrobial stewardship systems.

That makes this a clinical issue as well as a pharmaceutical regulatory compliance issue.

What Pharmacists, Retailers and Distributors Need to Follow

This part of the circular is especially relevant for retail pharmacies and medical stores.

CDSCO asks pharmacists, retailers and distributors to ensure that statutory requirements relating to Schedule H, H1 and other prescription medicines are followed.

Prescription Requirements Cannot Be Treated Casually

Where a medicine is subject to prescription-based retail sale, the sale should comply with the applicable Drugs Rules.

Self-Medication Should Not Be Encouraged

Pharmacists and retailers should not encourage or facilitate self-medication involving:

  • antibiotics, or
  • prescription-only NSAIDs.

Label Warnings Must Be Taken Seriously

Conditions of sale and prescribed warnings appearing on medicines should be observed.

That makes employee knowledge important. A retail business may have the correct medicine on the shelf but still face a compliance gap if the person supplying it does not understand the applicable sale condition.

What Does This Mean for Pharmacies and Medical Stores?

For pharmacies, this circular is a good reason to review actual counter-level practices.

The first question should not be, “Do we need a new CDSCO registration?”

The better questions are:

  • Are there proper supplies of medicines under prescription control?
  • Is there knowledge of Schedule H and H1?
  • Are warning labels being followed?
  • Are there proper supplies of antibiotics which encourage self-medication?
  • Are repeat requests for prescription-only painkillers being handled properly?
  • Is there a clear internal process where a medicine's regulatory status is uncertain?

None of these points requires a pharmacy to invent new paperwork merely for the sake of the circular.

But weak daily practices can still create a real compliance problem.

This is where pharmacy compliance services or a focused compliance gap assessment can help businesses check whether the written licence position and day-to-day sales practices actually match.

What Hospitals and Healthcare Institutions Should Strengthen

Hospitals are asked to take a broader view.

The circular specifically advises healthcare institutions to strengthen systems for:

  • rational prescribing,
  • monitoring of NSAID use,
  • monitoring of antibiotic use,
  • antimicrobial stewardship,
  • prescription review, and
  • appropriate patient counselling.

For a hospital, this may require coordination between clinicians, pharmacy teams and internal quality or compliance functions.

Prescribing Systems

Hospitals can review whether prescribing policies adequately cover the risks highlighted by CDSCO.

Medicine Monitoring

The institution should be able to identify patterns in NSAID and antibiotic use that require attention.

Prescription Review

Internal review can help catch inappropriate selection, dose or duration.

Patient Counselling

Patients should understand how the medicine has been prescribed and why it should not be shared or reused later.

The circular itself does not prescribe one mandatory committee, template or reporting form. Hospitals should therefore focus on meaningful controls rather than unnecessary paperwork.

Why Prescription Review Matters

A prescription is not automatically appropriate merely because it has been written.

Prescription review gives a hospital or healthcare institution another point at which medicine use can be checked.

For NSAIDs, the review may focus on patient risk, dose and duration.

For antibiotics, the review may focus on:

  • clinical indication,
  • antibiotic choice,
  • dose,
  • duration, and
  • microbiological information where relevant.

This fits directly with the concerns raised by CDSCO.

Why Patient Counselling Matters

The patient's role does not end when the medicine is supplied.

CDSCO's public-facing directions make this clear.

Patients need to understand that they should not:

  • extend treatment on their own,
  • share antibiotics,
  • save medicines for later self-treatment, or
  • repeatedly use painkillers without proper advice.

Good counselling supports the same responsible-use message the circular is trying to deliver.

Role of State and UT Drugs Control Authorities

CDSCO has also asked State and Union Territory Drugs Control Authorities to create awareness among healthcare professionals, pharmacists, retailers and the public.

The awareness effort is expected to cover:

  • risks linked with indiscriminate NSAID use,
  • risks linked with inappropriate antibiotic use, and
  • compliance with applicable provisions of the Drugs and Cosmetics Act and Drugs Rules.

The circular does not expressly announce a new national inspection schedule.

It should therefore not be reported as though a fresh enforcement campaign has already been formally launched.

NSAIDs, Kidney Risk and Chronic Kidney Disease

Kidney-related risk is central to the subject line of the circular, but the point needs to be explained carefully.

The document does not say that every person taking an NSAID will develop Chronic Kidney Disease.

Instead, CDSCO's concern is around inappropriate use and patient-specific risk.

The factors highlighted include:

  • repeated or prolonged use,
  • pre-existing kidney disease,
  • renal impairment,
  • dehydration,
  • cardiovascular disease, and
  • other conditions that may increase risk.

This is why the circular asks both patients and prescribers to treat NSAID use with more care.

Why CDSCO Is Discouraging Self-Medication

Self-medication sits at the centre of the circular because it removes professional assessment from the treatment decision.

With NSAIDs, repeated unsupervised use may overlook kidney-related or other risk factors.

With antibiotics, self-medication creates additional problems because the person may not know:

  • whether an antibiotic is needed,
  • which antibiotic is appropriate,
  • what dose is suitable, or
  • how long treatment should continue.

For this reason, the circular also tells pharmacies not to encourage or facilitate self-medication with prescription-only NSAIDs and antibiotics.

Antibiotics and Uncomplicated Viral Infections

CDSCO specifically says antibiotics should not be used for conditions where antibiotic treatment is not clinically indicated and refers to most uncomplicated viral infections as an example.

The important point here is not that a patient should diagnose the infection independently.

The opposite is true.

The circular's broader message is that treatment decisions should follow proper clinical assessment instead of self-diagnosis and self-medication.

Why Leftover Antibiotics Should Not Be Reused

Keeping leftover medicine may seem harmless, but the circular specifically tells the public not to use leftover antibiotics later on their own.

A medicine that was prescribed for an earlier condition should not automatically be treated as suitable for a later illness.

CDSCO also advises that prescribed antibiotics should not be shared with someone else.

For pharmacies and hospitals, this point can be reinforced through patient counselling.

Existing Legal Duties vs 2026 Advisory Focus

This table is useful because it prevents one of the biggest mistakes businesses can make with this circular: treating an existing legal requirement as though CDSCO invented it in September 2026.

Is a New CDSCO Registration Required?

No separate CDSCO registration is created by this circular.

The document does not establish a new:

  • application,
  • registration certificate,
  • approval portal,
  • certification process,
  • testing approval, or
  • renewal process.

Businesses must still comply with any licences, registrations and approvals that already apply to their activity, but those obligations exist independently of this circular.

For this particular update, CDSCO compliance services are more relevant than promoting a new CDSCO registration application.

Is There a New Compliance Deadline?

The circular is dated 21 September 2026.

It does not expressly provide a separate future deadline such as 30 days, 60 days or 90 days.

This makes sense because many of the legal requirements being referred to already form part of the existing drug-control framework.

Businesses should therefore focus on reviewing current practices rather than waiting for a future filing deadline.

Is There a New Government Fee?

No new fee, deposit or government charge is expressly specified in this circular.

Any cost incurred by a pharmacy or hospital in training staff, reviewing processes or strengthening internal systems would be an operational cost, not a fee imposed by this circular.

Does the Circular Create New Penalties?

The circular itself does not specify a new standalone fine or penalty.

It asks stakeholders to comply with the applicable provisions of the Drugs and Cosmetics Act, 1940 and Drugs Rules, 1945.

Businesses should therefore avoid two opposite mistakes:

  • assuming the circular has created a brand-new penalty structure, or
  • assuming there is no compliance exposure simply because this document does not list a fine.

Any legal consequence would depend on the applicable underlying provision and the actual conduct involved.

Compliance Risks Pharmacies Should Avoid

A pharmacy review after this circular should pay attention to practical risk areas rather than creating unnecessary documentation.

1. Supplying Prescription-Controlled Medicines Incorrectly

Where applicable prescription conditions exist, they should be followed.

2. Treating Antibiotics as Routine Over-the-Counter Products

The circular clearly discourages this approach.

3. Encouraging Repeat Self-Medication

Repeated sale of prescription-only painkillers or antibiotics without proper medical oversight can defeat the purpose of the regulatory controls.

4. Ignoring Label Conditions

A warning printed on a medicine should not be treated as decorative text.

5. Weak Staff Awareness

If only the licence holder understands the rule but counter staff do not, the business can still have an operational compliance gap.

Compliance Risks Hospitals Should Review

Hospitals face a different set of issues.

They should look at:

  • prescription of antibiotics without sufficient clinical basis,
  • unnecessary prolonged course of therapy with antibiotics without evaluation,
  • insufficient prescription evaluation,
  • inadequate surveillance of NSAID prescription in higher-risk groups,
  • limited antimicrobial stewardship oversight,
  • inadequate communication between clinical and pharmacy teams, and
  • weak patient counselling.

Not every weakness automatically amounts to a statutory violation, but these are areas that sit directly within the concerns raised by CDSCO.

CDSCO Compliance Checklist

Review Area What Should Be Checked Who Should Review Nature
Schedule H/H1 sale Prescription conditions Pharmacy team Existing legal compliance
Medicine classification Correct schedule identification Regulatory/compliance team Compliance review
Label warnings Awareness and observance Pharmacy staff Existing requirement
Self-medication Whether staff facilitate it Retail pharmacy CDSCO advisory focus
NSAID prescribing Risk, dose and duration Healthcare professionals CDSCO advisory focus
Antibiotic prescribing Indication, selection and duration Prescribers CDSCO advisory focus
Antimicrobial stewardship Internal programme effectiveness Hospital CDSCO advisory focus
Prescription review Adequacy of internal review Hospital/pharmacy Recommended control
Patient counselling Clarity of medicine-use advice Healthcare institution CDSCO advisory focus
Staff training Understanding of requirements Management/compliance Recommended control

Impact on Pharmacies and Medical Stores

For pharmacies, the biggest impact is likely to be operational rather than administrative.

There is no new application form to file.

Instead, businesses may need to ask whether staff actually follow the prescription and sale conditions already attached to the medicines they handle.

The following should be considered:

  • validating prescriptions,
  • training of staff members,
  • awareness of classifications,
  • selling methods,
  • label restrictions,
  • frequent customer demands for prescription medicines, and
  • internal escalation where the legal status of a product is unclear.

A structured pharmacy compliance service can be useful where a business wants to check these issues against its current operating practices.

Impact on Hospitals

Hospitals may face a wider internal review.

Prescribing, pharmacy operations and patient counselling all come into the picture.

A practical review may look at:

  • NSAID prescribing practices,
  • renal risk assessment,
  • antibiotic policies,
  • stewardship systems,
  • prescription review,
  • pharmacy-clinical coordination,
  • treatment-duration review, and
  • patient education.

The aim should be to improve actual control over medicine use, not simply add another layer of paperwork.

Impact on Healthcare Professionals

For doctors and other prescribers, the circular reinforces a more deliberate approach to medicine selection.

Before prescribing NSAIDs or antibiotics, the clinical situation and relevant patient factors should be assessed.

For NSAIDs, the focus includes renal risk, dehydration, cardiovascular disease and related factors.

For antibiotics, greater attention is expected around:

  • whether treatment is required,
  • which medicine is appropriate,
  • dose,
  • duration, and
  • microbiological information where relevant.

Impact on Patients

The public-facing message is probably the easiest part of the circular to understand.

Do not treat prescription medicines as routine household products.

The patient must:

  • refrain from multiple use of painkillers,
  • refrain from initiating antibiotic treatment on his own,
  • take treatment as prescribed by a doctor,
  • not share prescribed antibiotics,
  • not reuse medications left from previous treatments,
  • disclose relevant kidney-related conditions before using NSAIDs, and
  • seek medical advice when symptoms continue or return.

Business and Regulatory Perspective

This circular is unusual in one respect: its compliance impact is less about filing documents and more about how people behave inside the healthcare and pharmacy system.

A business may have a valid licence and still have weak daily practices.

A pharmacy may have all its registrations in place but still face problems if prescription medicines are casually supplied.

A hospital may have written policies but still need to check whether antibiotic review, monitoring and patient counselling happen consistently.

That is why the circular matters from a compliance perspective even though it does not introduce another application process.

For businesses, the useful question is not “What new form do we file?”

It is: “Are our current systems actually working the way the existing drug rules expect them to?”

What Businesses and Healthcare Institutions Should Do Next

1. Map the Medicines Being Handled

Identify products that fall under relevant prescription-controlled schedules.

Do not rely exclusively on general names such as “painkiller” or “antibiotic”.

2. Evaluate Prescribed Drug Sales

The pharmacy should investigate how prescribed drugs are sold at the counter and whether appropriate controls are properly applied.

3. Evaluate Staff Knowledge

The staff should be able to differentiate regular goods from medicines that have prescription controls applied.

4. Evaluate Labeling Conditions

Warnings and sale limitations related to medicines should be evaluated.

5. Check Self-Medication Practices

Look at whether customers are being supplied prescription-only medicines in a way that may encourage repeated self-use.

6. Review Hospital Prescribing Controls

Healthcare institutions should examine both NSAID and antibiotic prescribing practices.

7. Review Antimicrobial Stewardship

Hospitals should check whether the system is active and useful in practice rather than existing only on paper.

8. Strengthen Patient Counselling

Patients should understand the treatment they have been prescribed and the risks of sharing or reusing medicines.

9. Conduct a Compliance Gap Assessment

The process can help spot the gaps between the written policy and what is actually happening on the ground.

10. Monitor Other Regulatory Guidelines

Companies must keep an eye out for any further regulatory guidelines from CDSCO and State/UT Drugs Control Authority.

How Corpseed Can Help

The 2026 circular does not create a new CDSCO registration. For this reason, the most relevant support is CDSCO compliance services, drug-regulatory interpretation and practical compliance review.

CDSCO Compliance Services

Corpseed can assist pharmacies, pharmaceutical businesses and healthcare institutions in understanding CDSCO circulars and identifying the regulatory obligations that apply to their activities.

The objective is to separate what is legally required from what is advisory or recommended.

Pharmaceutical Regulatory Compliance Services

Businesses operating in the pharmaceutical sector often deal with multiple licences, schedules, sale conditions and regulatory directions.

Corpseed can support businesses in reviewing the regulatory framework that applies to their products and activities.

Drugs Rules Applicability Review

Where a business is unsure about the schedule or sale conditions applicable to a product, Corpseed can help review the relevant regulatory position.

This can be particularly useful where broad product descriptions do not clearly answer the compliance question.

Pharmacy Compliance Services

Pharmacies and medical stores can obtain support in reviewing:

  • prescription practices,
  • sale controls,
  • labeling requirements,
  • staff awareness, and
  • regulatory documentation.

Its purpose is to find gaps rather than to create unnecessary procedures.

Compliance Gap Assessment

By doing a proper compliance gap assessment, one can compare their own business practices with those regulatory requirements. It can include such aspects as:

  • dispensing,
  • prescription management,
  • product classification,
  • controls,
  • documentation, and
  • staff awareness.

Support in Compliance with Drug License Requirements

If a drug license has already been obtained, Corpseed can help your business ensure that its practices meet all regulatory requirements.

Healthcare Institution Compliance Support

Hospitals and other healthcare organisations can obtain support in reviewing their drug-related regulatory processes, internal policies and documentation.

Ongoing Drug Regulatory Compliance Support

CDSCO circulars and drug-control requirements can affect different parts of a business at different times.

Ongoing drug regulatory compliance services can help businesses assess new directions and decide whether any operational action is required.

Businesses that need support in understanding the impact of CDSCO directions can use Corpseed's CDSCO compliance services for applicability review, regulatory interpretation and compliance-gap assessment.

Key Takeaways

This circular from the CDSCO, which was released on 21st September 2026, has not introduced a new registration process. It is basically aimed at encouraging the responsible and safe use of NSAIDs and antibiotics.

  • CDSCO has warned against indiscriminate use of NSAIDs and antibiotics.
  • Most NSAIDs are referred to in the circular as Schedule H medicines.
  • Most antibiotic drugs are referred to as Schedule H1 medicines.
  • Pharmacists and sellers should adhere to prescription sale terms.
  • Prescriptions for these drugs should be made clinically.
  • These drugs need special caution when renal risk factors exist.
  • Antibiotic prescribing should follow antimicrobial stewardship principles.
  • Hospitals are asked to strengthen prescribing review, monitoring and patient counselling.
  • The circular does not itself create a new CDSCO registration, fee, application or standalone penalty.
  • State and UT Drugs Control Authorities have been asked to create awareness and support compliance with the applicable drug-control framework.

Document Preview

Embedded reference document

Fullscreen ↗

Related

Explore more updates from the same department.

Call